OBI Pharma, Inc.

As of June 30, 2026, OBI Pharma, Inc. carries a market capitalization of 3.96B, placing it among publicly traded companies globally. Its enterprise value stands at 4.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OBI Pharma, Inc.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, OBI Pharma, Inc. has 131.58M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 66.38, and the price-to-book ratio stands at 2.66.

These figures are as of June 30, 2026. The EV/Sales ratio of 88.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.62B versus a market cap of 3.96B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OBI Pharma, Inc. maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.33, indicating elevated leverage, while an interest coverage ratio of -124.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OBI Pharma, Inc. posted a negative return on equity (ROE) of -73.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.51, reflecting losses generated across the asset base. The company generates approximately 207,154.76 in revenue per employee across its workforce of 252.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.75 indicates how many times OBI Pharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, OBI Pharma, Inc. recorded an income tax benefit of -2.58M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.78B and -1.53B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, OBI Pharma, Inc.'s stock has declined approximately 4.32% over the past 52 weeks. The 50-day moving average sits at 34.84, while the 200-day moving average is 36.73.

Over the twelve months ended June 30, 2026, OBI Pharma, Inc. generated 52.20M in revenue and converted that into -1.53B in net income, yielding earnings per share of -15.42. EBITDA reached -1.43B, while operating income came in at -1.64B.

As of June 30, 2026, OBI Pharma, Inc. holds 496.96M in cash and equivalents against 446.14M in total debt, resulting in a net debt position of -179.31M. Total book value stands at 1.49B, with working capital of 614.28M providing operational flexibility.

OBI Pharma, Inc. produced -1.53B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.87M in capital expenditures, free cash flow totaled -1.55B - equivalent to -13.48 per share.

Over the twelve months ended June 30, 2026, OBI Pharma, Inc. posted a gross margin of -152.62, reflecting its pricing power and cost economics. The operating margin of -3,145.82 and net profit margin of -2,922.86 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.77, meaning OBI Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

OBI Pharma, Inc.'s most recent stock split took place on February 3, 2026 with a 2:1 split ratio.

As of June 30, 2026, OBI Pharma, Inc. has an Altman Z-Score of -1.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.